Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding: Technical Insights and Implications

Study Background and Research Question

The ongoing COVID-19 pandemic, caused by SARS-CoV-2, has motivated intensive research into the molecular determinants of viral entry. While it is established that the viral spike (S) protein binds to angiotensin-converting enzyme 2 (ACE2), new evidence suggests additional host receptors such as AXL and neuropilin-1 (NRP1) can facilitate infection, especially in tissues with low ACE2 expression. The renin-angiotensin-aldosterone system (RAAS)—long studied for its roles in blood pressure and fluid balance—generates a spectrum of bioactive peptides, including Angiotensin II and its derivatives like Angiotensin III (sequence: Arg-Val-Tyr-Ile-His-Pro-Phe). These peptides are not only aldosterone secretion inducers and pressor activity mediators but also interact with AT1 and AT2 receptors, implicating them in a range of physiological and pathophysiological responses. The central question addressed by Oliveira et al. (2025) is whether these endogenous angiotensin peptides modulate SARS-CoV-2 spike protein binding to its host cell receptors, thereby influencing viral tropism and infectivity (paper).

Key Innovation from the Reference Study

This study provides the first systematic analysis of how endogenous angiotensin peptides, differing by specific N- and C-terminal truncations or modifications, alter the binding affinity of the SARS-CoV-2 spike protein to multiple host receptors. Notably, the authors demonstrate a substantial enhancement of spike–AXL interaction mediated by N-terminally truncated peptides such as Angiotensin III and Angiotensin IV, revealing a previously unappreciated regulatory axis between the RAAS and viral entry (paper).

Methods and Experimental Design Insights

Oliveira et al. employed antibody-based binding assays to quantitatively assess the interaction between SARS-CoV-2 spike protein and three host receptors: ACE2, NRP1, and AXL. The experimental design included exposing these receptors to a panel of angiotensin peptides—ranging from angiotensin I (1–10) and II (1–8) to N- and C-terminally truncated derivatives (e.g., angiotensin III [2–8], angiotensin IV [3–8], angiotensin (1–7), and angiotensin (1–6)). The impact of site-specific modifications, such as tyrosine substitutions or phosphorylation, was also probed. Quantitative changes in spike–receptor binding were measured as fold-increase over baseline, providing direct evidence for peptide-specific modulation (paper).

Core Findings and Why They Matter

The study’s most salient findings are:

• Angiotensin II increased spike–AXL binding by approximately two-fold, with no observed effect on ACE2 or NRP1 (paper).
• C-terminally truncated peptides (e.g., angiotensin (1–7), (1–6)) retained similar spike–AXL enhancement as angiotensin II.
• N-terminal truncations—as in angiotensin III (2–8) and angiotensin IV (3–8)—produced an even greater enhancement of spike–AXL binding (up to 2.7-fold with angiotensin IV; angiotensin III also increased binding above angiotensin II baseline) (paper).
• Site-specific modifications, particularly at the tyrosine residue within the Arg-Val-Tyr-Ile-His-Pro-Phe sequence, further increased spike–AXL binding, implicating this residue as a key determinant of effect.
• Angiotensin IV, but not Angiotensin III, also enhanced spike binding to ACE2 and NRP1, suggesting sequence-specific effects on receptor cross-reactivity.

These results indicate that endogenous angiotensin peptides, especially those generated by N-terminal cleavage (such as Angiotensin III), may potentiate SARS-CoV-2 entry via non-ACE2 pathways. This highlights a mechanistic bridge between cardiovascular peptide signaling and viral pathogenesis (paper).

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on Angiotensin III’s role within the RAAS and its experimental applications. GSK1363089 delves into the molecular mechanisms of Angiotensin III as a renin-angiotensin-aldosterone system peptide, emphasizing its receptor selectivity and value in dissecting AT1/AT2 signaling pathways. BTZ043 focuses on applied protocols for cardiovascular and viral pathogenesis models, highlighting Angiotensin III’s reproducibility and translational flexibility. The present study extends these insights by demonstrating that Angiotensin III not only acts as a pressor activity mediator and aldosterone secretion inducer but also modulates viral spike–receptor interactions, thus bridging cardiovascular and infectious disease research. The protocol- and scenario-driven troubleshooting guides (GSK1363089, angiotensin-1-7.com) reinforce the peptide’s role in high-fidelity assay design, now further supported by evidence of relevance in viral entry workflows.

Protocol Parameters

• Binding assay | 2–3 µM peptide | Quantification of spike–AXL interaction | Reflects concentrations used to observe fold-increase in binding | paper
• Peptide solubility in water | ≥23.2 mg/mL | Stock preparation/applicability in aqueous assays | Ensures robust peptide delivery for in vitro studies | product_spec
• Peptide solubility in ethanol | ≥43.8 mg/mL | Alternate solvent compatibility | Enables flexibility in protocol design | product_spec
• Peptide solubility in DMSO | ≥93.1 mg/mL | High-concentration stock solutions | Suitable for protocols requiring concentrated peptide stocks | product_spec
• Storage | Desiccated at –20°C | Long-term peptide stability | Maintains experimental reproducibility | product_spec
• Assay temperature | Room temperature (20–25°C) | Standard for receptor–ligand binding assays | Reduces thermal denaturation risk | workflow_recommendation

Why this cross-domain matters, maturity, and limitations

Bridging cardiovascular peptide research and viral pathogenesis is of high significance, as it suggests that disease states or treatments influencing endogenous angiotensin peptide levels could impact susceptibility to SARS-CoV-2 infection. However, the findings are currently based on in vitro binding assays and do not directly demonstrate altered viral infectivity in vivo. There is also a need to clarify whether these peptide-induced enhancements translate to different tissue environments or patient populations. Thus, while the cross-domain bridge is mechanistically compelling, practical and clinical implications remain to be fully validated (paper).

Limitations and Transferability

The primary limitation is the use of antibody-based in vitro binding assays, which, while precise for mechanistic dissection, may not fully recapitulate the cellular and systemic complexity of in vivo infection. The peptide concentrations used may differ from physiological levels, and the downstream consequences of increased spike–AXL binding—such as actual viral entry or replication—were not directly measured. Therefore, findings should be interpreted as foundational, warranting further investigation in physiological models. Transferability to clinical or translational settings requires additional validation (paper).

Research Support Resources

For researchers aiming to replicate or extend these workflows, Angiotensin III (human, mouse) (SKU A1043, APExBIO) offers a well-characterized, high-purity peptide with validated solubility and stability parameters, supporting both cardiovascular and viral binding assay applications (product_spec). Peer-reviewed workflow guides (GSK1363089, angiotensin-1-7.com) provide further technical detail for optimizing RAAS peptide assays and troubleshooting experimental challenges in both cardiovascular and emerging infectious disease contexts.